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TO THE EDITOR
Nevus spilus, also known as speckled
lentiginous nevus, is a congenital hyper-
pigmented patch, which progressively
evolves, developing dark macules and
papules during childhood and adoles-
cence (Vidaurri-de la Cruz and Happle,
2006) (Figure 1a, b). Over time, nevus
spilus has been reported to give rise to
common lentigines, melanocytic nevi,
Spitz nevi, and melanoma (Bolognia,
1991; Aloi et al., 1995; Betti et al.,
1997; Vente et al., 2004). These conge-
nital lesions are postulated to result
from a postzygotic genetic alteration
of the melanocytic lineage, which gives
rise to a clone of melanocytes predis-
posed to developing neoplasms (Happle,
1993).
Using exome sequencing, we recently
identified an activating HRAS point
mutation (c.37G-4C, p.Gly13Arg) in a
nevus spilus giving rise to agminated
Spitz nevi that was absent from adjacent
normal skin (Sarin et al., 2013).
However, it remained unclear whether
this mutation is unique to this atypical
case or represented a common mutation
in nevi spili. In this report, we identify
the presence of the HRAS point muta-
tion (c.37G-4C, p.Gly13Arg) in eight
additional sporadic nevi spili, thus
implicating the HRAS mutation (c.37G-
4C, p.Gly13Arg) as the predominant
causative mutation for nevi spili.
Genomic DNA was isolated from
paraffin tissue biopsies of eight samples
that were clinically diagnosed as nevi
spili by board-certified dermatologists
and confirmed as being consistent with
nevi spili by board-certified dermato-
pathologists. These tissue biopsies were
obtained from the lentiginous areas
as well as the nevi within the lesion.
Phenotypic and histopathologic data on
each nevus spilus sample are detailed in
Supplementary Table S1 online. Initial
attempts at Sanger sequencing of whole
paraffin sections for the presence of
the HRAS point mutation (c.37G-4C,
p.Gly13Arg) were negative. We hypo-
thesized that the causative mutation
may be undetectable by traditional
Sanger sequencing as nevi spili melano-
cytes comprise a minute fraction of the
total cells in the section. One method
for enrichment of this small population
is through laser capture microdissection.
However, this technique is time and
labor intensive and thus not easily
adaptable into a screening assay. To
enrich for a potential HRAS mutation,
we used a rapid screening assay exploit-
ing the fact that the HRAS point mutation
(c.37G-4C, p.Gly13Arg) obliterates an
Aci1 enzymatic digestion site (Supple-
mentary Figures S1, S2 and Supple-
mentary Methods online). Briefly, DNA
isolated from whole paraffin sections
of nevi spili was amplified with HRAS
primers 50-CCTATCCTGGCTGTGTCCT
G-30 and 50-CAGGAGACCCTGTAGGAG
GA-30 spanning exon 2. The HRAS
exon 2 amplicon was then subjected to
digestion for 16hours at 37 degrees with
Aci1, which preferentially digests wild-
type HRAS sequences in the sample,
thereby enriching for DNA sequences
containing the HRAS mutation (c.37G-
4C, p.Gly13Arg). Following digestion,
the DNA was subjected to a second
round of amplification with nested HRAS
primers 50-CTCACCTCTATAGTGGGGT
CGT-30 and 50-TGAGGAGCGATGACG
GAATA-30 spanning the digestion site.
Sanger sequencing using the internal
primers in both directions now detected
this point mutation in all eight samples
but not in normal control skin (Figure 2a
and b). The mutation was also confirmed
using an independent set of HRAS
primers 50-ATGACGGAATATAAGCTG-30
and 50-CTCTATAGTGGGGTCGTA-30
for the second round amplification and
Sanger sequencing. Although the diges-
tion using Aci1 was incomplete as
evidenced by the persistent detection
of the wild-type allele, it was sufficient
to enrich the proportion of DNA con-
taining the HRAS mutation to detectable
levels.
Recently, activating HRAS mutations
were identified in the keratinocytes andAccepted article preview online 3 January 2014; published online 30 January 2014
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KY Sarin et al.
HRAS Mutation in Nevus Spilus
1766 Journal of Investigative Dermatology (2014), Volume 134
melanocytes of patients with phako-
matosis pigmentokeratotica, suggesting
a postzygotic mutation in an early com-
mon progenitor cell. We hypothesized
that sporadic nevus spilus is likely to
occur from a postzygotic mutation
affecting specifically the melanocytic
lineage. To assess this, we performed
laser capture microdissection to isolate
DNA from the lentiginous melanocytes
and junctional melanocytic nests, the
superficial epidermis, and the surround-
ing dermis on two nevus spilus samples.
In both cases, the HRAS mutation
(c.37G-4C, p.Gly13Arg) was specifi-
cally detected in the melanocyte isolate
but not in the keratinocytes or dermal
fibroblasts (Figure 2c, Supplementary
Figure S3 online). These data suggest
that sporadic nevi spili result from a
postzygotic mutation in the melano-
cytic lineage. Of note, the percent of
DNA containing the HRAS muta-
tion (c.37G-4C, p.Gly13Arg) was
less than the fifty percent that was
expected of a heterozygous activa-
ting mutation. One possible expla-
nation for this finding is the neighboring
keratinocyte contamination in the
laser capture microdissection of the
melanocytes.
RAS promotes cell growth predomi-
nantly through activation of the mito-
gen-activated protein kinase (MAPK)
signal-transduction pathway. To evalu-
ate downstream MAPK signaling, we
performed phosphorylated ERK (pERK)
immunostaining on a set of five nevi
spili with confirmed HRAS mutations.
Serial immunohistochemistry for pERK
and microphthalmia-associated trans-
cription factor (MITF), a marker of
melanocytes, revealed acquired pERK
staining in the melanocytes not detected
in the neighboring keratinocytes or stro-
mal fibroblasts, indicating a selective
activation of the MAPK pathway in the
melanocytic lineage (Figure 2d). The
secondary antibody–only control was
negative (Supplementary Figure S4
online). Our results implicate the acti-
vating HRAS mutation (c.37G-4C,
p.Gly13Arg) as the predominant muta-
tion in nevus spilus and demonstrate
that this mutation is sufficient to cause
activation of the MAPK signaling
pathway. Nevi spili can manifest hetero-
geneously with macular and/or papular
lesions and can be seen in different
settings, with macular lesions seen in
phacomatosis spilorosea and papular
lesions seen in phacomatosis pigmento-
keratotica (Happle, 2010). Our study is
unable to fully assess whether HRAS
mutations are represented differentially
in these two phenotypes due to limited
clinical phenotypic detail and sample
size. Furthermore, it is likely that other
mutations may also underlie nevi spili
as, in addition to the HRAS mutation
p.Gly13Arg, the activating HRAS muta-
tion p. Gln61Arg has been identified in
two nevi spili in phacomatosis pigmen-
tokeratotica patients (Groesser et al.,
2013). Future studies are needed to
investigate the mechanisms underlying
Figure 1. Clinical and histopathological features of a nevus spilus. (a) Photograph of a tan patch on the
left abdomen speckled with 1–2 mm hyperpigmented macules. (b) Hematoxylin and eosin staining of a
nevus spilus biopsy showing scattered melanocytes and melanocytic nests along the dermo–epidermal
junction. Bar¼50mm.
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Figure 2. Activating HRAS mutation (c.37G-4C, p.Gly13Arg) in nevus spilus. (a) Sanger sequencing
of Aci1-digested DNA from nevus spilus and control normal skin demonstrating the HRAS mutation
in the nevus spilus but not in normal skin. (b) Table of HRAS mutations showing that the HRAS mutation
(c.37G-4C, p.Gly13Arg) is present in all eight nevi spili but is undetectable in the control normal skin. wt,
wild type. (c) Sanger sequencing from microdissection of two nevi spili samples demonstrates the HRAS
mutation (c.37G-4C, p.Gly13Arg) in the melanocytic isolate and not in the keratinocyte isolate or dermal
fibroblasts. Bar¼50mm. (d) Serial immunohistochemical staining for phosphorylated ERK (pERK), a
downstream effector of the RAS/MAPK pathway (left panel), and microphthalmia-associated transcription
factor, a marker of melanocytes (right panel), reveals selective activation of the RAS/MAPK pathway in the
melanocytes (arrow), but not in the surrounding keratinocytes or dermal fibroblasts. Bar¼ 50mm.
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the phenotypic heterogeneity of nevi
spili.
HRAS mutations have recently been
demonstrated in a number of hamarto-
matous cutaneous neoplasms including
epidermal nevi and nevus sebaceous
(Groesser et al., 2012; Hafner et al.,
2012; Levinsohn et al., 2012; Sun et al.,
2013). When these alterations occur
early in development or affect multiple
cell lineages, they can result in develop-
mental syndromes called ‘RASopathies,’
such as Schimmelpenning, epidermal
nevus syndrome, and phacomatosis pig-
mentokeratotica (Hafner and Groesser,
2013). The HRAS point mutation
(c.37G-4C, p.Gly13Arg), in particular,
appears to be overrepresented among
HRAS mutations in these cutaneous con-
genital conditions. This mutation allows
constitutive activation of RAS pathway
likely facilitating the development of
secondary neoplasms through accrual of
additional genetic alterations.
Our finding adds sporadic nevus
spilus to the spectrum of congenital
cutaneous lesions that harbor activating
mutations in HRAS. In nevus spilus, we
speculate that the melanocytic neo-
plasms that arise from these tan patches
likely acquire additional genetic altera-
tions that enable progression. Indeed,
we have recently demonstrated such a
secondary change through amplification
of HRAS in Spitz nevi arising out of a
nevus spilus (Sarin et al., 2013). How-
ever, the secondary mutations that give
rise to the diverse spectrum of melano-
cytic neoplasms have not yet been
identified. The knowledge of the
genetic basis of nevus spilus represents
a further step towards understanding the
genetic etiology underlying melanocytic
neoplasms. In addition, these lesions
represent a unique opportunity to study
the genetic alterations that allow pro-
gression from a nevus spilus to a nevus
or melanoma in the setting of constitu-
tive RAS/MAPK activation.
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Decreased Expression of the Chromatin Remodeler ATRX
Associates with Melanoma Progression
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TO THE EDITOR
ATRX is a member of the SWI/SNF
family of chromatin remodelers, origin-
ally identified as mutated in patients
with Alpha Thalassemia/Mental Retar-
dation, X-linked syndrome. The protein
product contains several highly con-
served domains, including an ADD
(ATRX-DNMT3-DNMT3L) domain that
binds methylated histone H3 at lysine 9
and an ATPase domain responsible for
its remodeling activities (Ratnakumar
and Bernstein, 2013). Recently, whole-
genome sequencing studies identified
ATRX mutations in multiple tumors,
including those of neural crest cell
origin: neuroblastoma, low-grade glioma,
and glioblastoma (Heaphy et al., 2011a;
Jiao et al., 2011; Cheung et al., 2012;Accepted article preview online 27 January 2014; published online 27 February 2014
Abbreviations: ATRX, alpha thalassemia/mental retardation, X-linked; IHC, immunohistochemistry
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